Not yet reviewed — this article is pending editorial review by Lyrea.

2-FEA

2-Fluoroethamphetamine

o-Fluoroethamphetamine, ortho-Fluoroethamphetamine

Psychoactive Class

Stimulant Entactogen

Chemical Class

Amphetamine (substituted)

2-FEA is a novel synthetic stimulant of the substituted amphetamine class. It is the N-ethylated homolog of 2-fluoroamphetamine (2-FA), featuring an ethyl group bound to the terminal amine of the amphetamine backbone.¹ 2-FEA produces classical stimulant and entactogenic effects, including stimulation, enhanced focus, and euphoria. It has limited documented history of human use and is primarily available through the online research chemical market.

Dosage & Duration

Dosage

Threshold~15 mg

Light20-30 mg

Moderate30-40 mg

Strong40-60 mg

Heavy60+ mg

Duration

Onset5-15 minutes

Come Up5-10 minutes

Peak30-60 minutes

Offset30-60 minutes

After Effects1-3 hours

Total1-2.5 hours

Subjective Effects

The subjective effects of 2-FEA are very poorly documented, with little formal or anecdotal characterization available. What limited reporting exists describes it as a mild stimulant of the substituted amphetamine family, producing wakefulness and modest physical energy rather than a strongly recreational or perceptually altering experience.

Physical

Mild stimulation and increased wakefulness are the primary reported physical effects.

Stimulation

Wakefulness

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)

Mandelin(MD)

Liebermann(LB)

Morr(MO)

PROtestkit.eu

Pharmacology

Pharmacodynamics

In an in-vitro human monoamine-transporter uptake assay, 2-FEA inhibited DAT and NET at similar submicromolar concentrations and inhibited SERT at a concentration about eight times higher. These data support a predominantly catecholamine-transporter uptake-inhibition profile in that assay.²

Uptake-inhibition IC50 values do not establish that 2-FEA is a transporter substrate or monoamine-releasing agent, and they do not determine clinical potency, dose, or safety in humans.²

Pharmacokinetics

The available transporter study is in vitro and does not provide human absorption, distribution, metabolism, elimination, bioavailability, or half-life data for 2-FEA. Human pharmacokinetics and metabolite profiles therefore remain uncharacterized by this evidence.²

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholCocaineDXMDissociativesMAOIsMDMAMXENBOMe compoundsStimulantsTramadol

TripSit

Tolerance

Full Tolerance

Repeated 2-FEA use over time can lead to tolerance for many effects, so similar results may require larger doses.

Baseline Reset

1-2 weeks

Half Tolerance

3-7 days

Cross Tolerance

Dopaminergic stimulants

Harm Potential

Addiction & Dependence

Psychological

Moderate

Moderately addictive with a high potential for abuse and capable of causing psychological dependence among certain users. Compulsive redosing is reported, and cravings may develop with chronic use.

Physical

Low

Withdrawal effects may occur if a person suddenly stops usage after developing addiction, though specific physical withdrawal symptoms are not well-documented. The emphasis in available literature is on psychological rather than physical dependence.

Psychosis Risk

Psychosis is listed as a potential after effect during the comedown period. Anxiety, paranoia, and delusions typically occur with overly high doses or after redosing and staying awake for extended periods, following the pattern typical of stimulant use.

History & Culture

2-FEA emerged as a novel psychoactive substance distributed through online research chemical vendors. Limited formal documentation exists regarding its precise origins, initial synthesis, or the circumstances of its introduction to the recreational drug market.…

Legality

By Country

United StatesUnscheduled

Not a federally controlled substance as of 2011. However, prosecution may be possible under the Federal Analogue Act when sold or possessed with intent for human consumption, as it is structurally related to scheduled amphetamines.

FranceNot scheduled

As of December 2024, 2-FEA is not explicitly scheduled under French drug control legislation. Possession is technically legal, though the substance exists in a regulatory gray area.

NetherlandsLegal (pending review)

Currently unscheduled and legal to possess. However, 2-FEA falls within a substance group that may be prohibited under recently passed legislation targeting new psychoactive substances.

SwitzerlandControlled (Verzeichnis E)

Regulated as a controlled substance under Verzeichnis E point 130 as a defined derivative of α-methylphenethylamine.⁷ Exemptions exist for legitimate scientific or industrial applications.

CanadaSchedule I (analogue)

Considered a Schedule I controlled substance as an analogue of amphetamine under Canadian drug scheduling laws.³

GermanyNpSG controlled

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016.⁴ Production and import with intent to market, administration to others, and trading are punishable offenses.⁵ Possession is prohibited but not subject to criminal penalties.

New ZealandSchedule 3

Classified as a Schedule 3 controlled substance due to its structural relationship to amphetamine under New Zealand's analogue provisions.⁶

United KingdomClass A

Controlled as a Class A substance under the amphetamine analogue clause of the Misuse of Drugs Act 1971.⁸ Class A classification carries the most severe penalties under UK drug law.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 2-FEA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.